Atopic Dermatitis

The DELTA 3 trial evaluated the long-term safety of twice-daily as-needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.

LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial.

What’s more, patients...

First fully human monoclonal antibody IL-13 and IL-4-inhibitor significantly improves AD severity and is well tolerated, offering expanded biologic treatment options for eczema patients.

The results of a phase 3 trial expands on the efficacy and safety profile of tralokinumab, the first monoclonal antibody (mAb) that targets IL4Rα, blocking signaling of interleukin (IL)-13 and IL-4. A...

Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with lebrikizumab monthly maintenance dosing at two years.

Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease s...

The results of a new study show that BNP likely plays a role in itch activation.

The brain natriuretic peptide (BNP) may play a role in activating atopic dermatitis, according to new research in mice.

“BNP is expressed in sensory neurons, the neurons responsible for conveying sen...

Researchers discovered that neurons respond to IL-31 by triggering a scratch and preventing immune cells from overreacting and causing more widespread irritation. 

In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein ...

Additional analysis from the DELTA 2 trial concluded that twice-daily application of delgocitinib cream resulted in minimal systemic exposure, further supporting its safety profile.

Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cre...

Lebrikizumab also demonstrated improvements in absolute response in the skin over 16 weeks in patients with moderate-to-severe AD in the ADvocate 1 and 2 Phase 3 trials.

Lebrikizumab showed clinical improvements in combination with topical corticosteroids (TCS) in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD) that was not adequately co...

The treatment with tralokinumab produces sustained responses that offer real benefits to the people living with AD over time.

Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup a...

Patients reported a significant improvement in scaling, itch, and pain at Week 8, with significantly more individuals treated with roflumilast foam achieving a Psoriasis Symptom Diary (PSD) score of 0, or clear, compared to vehicle.

Arcutis’ roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints when compared to vehicle, according to patient-reported outcome data...

The company plans to file an sNDA for VTAMA cream in AD in Q1 2024.

Dermavant’s VTAMA (tapinarof) Cream, 1% reduces pruritus in adults and kids with atopic dermatitis as early as 24 hours after the first application, according to new data from ADORING 1 and ADORING 2 ...